MONDAY, Sept. 16, 2024 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to...
Vous n'êtes pas connecté
MONDAY, Sept. 16, 2024 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis.Tremfya is the first and only dual-acting interleukin-23 inhibitor...
MONDAY, Sept. 16, 2024 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to...
HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...
HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...
WEDNESDAY, Sept. 18, 2024 -- The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and...
INDIANAPOLIS, Sept. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved...
FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.
With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.
With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.
FRIDAY, Sept. 13, 2024 -- Over 5 million Americans could benefit if the U.S. Food and Drug Administration approves the "magic mushroom" psychedelic...
FRIDAY, Sept. 13, 2024 -- Over 5 million Americans could benefit if the U.S. Food and Drug Administration approves the "magic mushroom" psychedelic...